12003 European Society of Hypertension-Euroupean Society of cardiology.guidelines for the management of arterial hypertension[J].J Hypertension,2003;21:1001-53.
2WHO/ISH.Hypertension Guidelines Committee.1999 world health organization international society of hypertension guidlins for the management of hypertension[J].J Hypertens,1999;17(200):151-85.
3Adams MA,Trudeau L.Irbesartan:Review of pharmacology and comparative properties[J].Can J Clin Pharmacol,2000;7(1):22-31.
4Richard A,Richard AR,Lin CS,et al .Dose-related efficacy of irbesartan for hypertension[J].Hypertension,1998;31(5):1311-6.
5Mimran A,Ruilope L,Kerwin L,et al.A randomized,double blind comparision of the angiotension antagonist,irbesartan,with the full dose range of enalapril for the treatment of mild to moderate hypertension[J].J Hum Hyperten,1998,12(3):203-8.
6Vachharajami N, Chang SY, Shu WC,et al.Aboslute bioavailability of irbesartan, an angiotensionⅡreceptor antagonist,in man(abst)[J].Pharm Res,1995;12(Suppl):s418.
